{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-013927","form_type":"8-K","ticker":"OLMA","cik":"0001750284","company_name":"Olema Pharmaceuticals, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.083786+00:00","generated_at":"2026-06-12T02:24:02.462928+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Olema reports Q2 net loss $20.1M; cash $167.4M; Phase 3 trial on track Q4 2023","bullets":["Net loss $20.1M for Q2 2023, down from $32.9M in Q2 2022; R&D expenses $18.0M.","Cash, cash equivalents and marketable securities $167.4M as of June 30, 2023, funding operations into Q2 2025.","OPERA-01 pivotal Phase 3 trial of palazestrant (OP-1250) monotherapy to enroll first patient in Q4 2023.","Palazestrant Phase 2 monotherapy data as oral presentation at ESMO Congress October 22, 2023.","Interim Phase 1b/2 combination data with CDK4/6 inhibitors to be presented in Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-013927","json":"https://secwatch.observer/filing/0001558370-23-013927.json","markdown":"https://secwatch.observer/filing/0001558370-23-013927.md","text":"https://secwatch.observer/filing/0001558370-23-013927.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750284/000155837023013927/0001558370-23-013927-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750284/000155837023013927/olma-20230808x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:24:02.462928+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2026ca22f47a10bd611867fba4c14a2175a38194","claim":"Olema Pharmaceuticals, Inc. reported financial results for the quarter ended June 30, 2023.","evidence_excerpt":"On August 8, 2023, Olema Pharmaceuticals, Inc. (the “Company”) reported its financial results for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750284/000155837023013927/0001558370-23-013927-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}